Prevention of osteoporosis and fractures.
Osteoporosis and low bone density are associated with a risk of fracture as a result of even minimally traumatic events. The estimated lifetime risk of osteoporotic fracture is as high as 50 percent, especially in white and Asian women. The use of caffeine, tobacco and steroids is associated with a decrease in bone density. Cognitive impairment, vision problems and postural instability increase the risk of falling and sustaining a fracture. Medications such as long-acting sedative hypnotics, anticonvulsants and tricyclic antidepressants also increase this risk. Combinations of clinical and radiographic findings can predict fracture risk more effectively than bone densitometry, but often only after the first fracture has occurred. The addition of dietary calcium and/or vitamin D is clearly both cost-effective and significant in reducing the likelihood of fractures. Bisphosphonates reduce fracture risk but at a cost that may be prohibitive for some patients. Estrogen and estrogen-receptor modulators have not been well studied in randomized trials evaluating the reduction of fractures, but they are known to increase bone density. Pharmacologic therapy and the reduction of sensory and environmental hazards can prevent osteoporotic fractures in some patients.
University of Kansas School of Medicine-Wichita, USA.
P
P
Ullom-Minnich
D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000819:agonists; D012968:Etidronic Acid / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000517:prevention & control; D010880:Piperidines / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride; D012306:Risk; D012307:Risk Factors; D014807:Vitamin D / Q000627:therapeutic use
D004967:Estrogens; D010880:Piperidines; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; D012968:Etidronic Acid; D002118:Calcium; D019386:Alendronate